BioRestorative Therapies Inc BRTX:NASDAQ

Earnings Announcement Next Earnings date is expected on 08/15/2022
Last Price$3.00NASDAQ Previous Close - Last Trade as of 3:38PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.95 (2)
Ask (Size)$3.24 (3)
Day Low / HighN/A - N/A
Volume10.1 K

Read more news Recent News

BioRestorative Therapies Enrolls First Patient in Phase 2 Trial of Chronic Lumbar Disc Disease Therapy
8:02AM ET 6/30/2022 MT Newswires

BioRestorative Therapies (BRTX) said Thursday it enrolled the first patient in the phase 2 clinical trial for its chronic lumbar disc disease therapeutic. ...

BioRestorative Therapies Secures Second Site for Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease; Shares Rise Pre-Bell
8:13AM ET 6/22/2022 MT Newswires

BioRestorative Therapies (BRTX) said Wednesday it has entered into an agreement with a second site for a Phase 2 clinical trial of its investigational stem...

BioRestorative Therapies Begins Site Initiation for Phase 2 Study of BRTX-100 to Treat Chronic Lumbar Disc Disease
8:32AM ET 6/13/2022 MT Newswires

BioRestorative Therapies (BRTX) said Monday that it has begun site initiation for its phase 2 clinical trial targeting chronic lumbar disc disease. The...

BioRestorative Therapies Picks 10 US Clinical Sites for Trial of Spine Condition Treatment; Shares Gain Pre-Bell
8:48AM ET 4/18/2022 MT Newswires

BioRestorative Therapies (BRTX) said Monday it has picked 10 out of a planned 15 clinical sites for a phase 2 trial of its BRTX-100 investigational drug...

View all Commentary and Analysis

CFO Trading Anomaly For April: Revealing Top Insider Buys In Declining Markets
11:10AM ET 4/19/2022 Seeking Alpha

Company Profile

Business DescriptionBiorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The firm is developing the following scientific programs: brtxDISC, which offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures and ThermoStem, which involves the use of a cell-based, brown adipose tissue construct, treatment for metabolic disease, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. Its products are sold under the BRTX-100, ThermoStem and Stem Pearls trademarks. The company was founded on June 13, 1997 and is headquartered in Melville, NY. View company web site for more details
Address40 Marcus Drive
Melville, New York 11747
Number of Employees9
Recent SEC Filing08/05/2022PRE 14A
Chairman, President & Chief Executive OfficerLance Alstodt
Chief Financial OfficerRobert E. Kristal
Secretary, Director & VP-Research & DevelopmentFrancisco J. Silva
Vice President-Quality & ComplianceRobert Paccasassi

Company Highlights

Price Open$2.98
Previous Close$2.97
52 Week Range$2.75 - 26.80
Market Capitalization$10.9 M
Shares Outstanding3.6 M
SectorHealth Technology
Next Earnings Announcement08/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$14.09
Beta vs. S&P 500N/A
Revenue$111.0 K
Net Profit Margin-76,059.35%
Return on Equity-404.85%

Analyst Ratings as of 11/30/2021

Consensus RecommendationConsensus Icon
Powered by Factset